anti-Synuclein, alpha (Non A4 Component of Amyloid Precursor) (SNCA) Antibodies

Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein.

list all antibodies Gene Name GeneID UniProt
Anti-Mouse SNCA SNCA 20617 O55042
Anti-Human SNCA SNCA 6622 P37840
Anti-Rat SNCA SNCA 29219 P37377
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

More Antibodies against Synuclein, alpha (Non A4 Component of Amyloid Precursor) Interaction Partners

Rhesus Monkey Synuclein, alpha (Non A4 Component of Amyloid Precursor) (SNCA) interaction partners

  1. Overexpression of mutant alpha-synuclein causes age-dependent pathological changes in brain.

Mouse (Murine) Synuclein, alpha (Non A4 Component of Amyloid Precursor) (SNCA) interaction partners

  1. Data suggest that endocytosis is the principal mechanism by which proteopathic alpha-synuclein aggregates are internalized in primary hippocampal neurons in culture; aggregates are rapidly trafficked along endosomal/lysosomal pathway, where most of the material remains for days as proposed in neurodegenerative synucleinopathies.

  2. LRRK2 (show LRRK2 Antibodies) negatively regulates the clearance of alphaSYN accompanied by down-regulation of the endocytosis pathway; LRRK2 (show LRRK2 Antibodies) in microglia may function as the offending molecule responsible for neurodegeneration, in terms of down-regulation of alphaSYN clearance.

  3. sideroflexin 3 (SFXN3 (show SFXN3 Antibodies)) was found to be a mitochondrial protein (show COX6B2 Antibodies) localized to the inner mitochondrial membrane.

  4. The ability of monomeric alpha-synuclein to enhance ATP synthase efficiency under physiological conditions may be of importance when alpha-synuclein undergoes the misfolding and aggregation

  5. Rab7 (show RAB7A Antibodies) accumulated in GCase (show GBA Antibodies) deficient cells, supporting the notion that lysosomal recycling is impaired. Since recombinant GCase (show GBA Antibodies) can reverse ALR (show GFER Antibodies) impairment, we anticipate that strategies to restore GCase (show GBA Antibodies) activity in the brains of both sporadic patients with PD and those with GBA1 (show GBA Antibodies) mutations will improve autophagy lysosomal pathway, preventing the accumulation of a-synuclein and spread of pathology.

  6. Study showed that apoptosis is an important form of cellular degeneration in lipopolysaccharide (LPS (show TLR4 Antibodies)-sensitized hypoxic-ischemic (HI) injury in the immature brain. Loss of PINK1 (show PINK1 Antibodies) can protect the immature brain against cell apoptosis induced by LPS (show TLR4 Antibodies)-sensitized HI injury. Moreover, alpha-Syn plays a neuroprotective role in LPS (show TLR4 Antibodies)-sensitized HI brain damage in PINK1 (show PINK1 Antibodies)-knockout neonatal mice

  7. Genetic manipulation of sirtuin 2 (show SIRT2 Antibodies) levels in vitro and in vivo modulates the levels of alpha-synuclein acetylation, its aggregation, and autophagy.

  8. These results indicate that fragmented amyloid-like aggregates of short alpha-syn fibrils are the key pathogenic seeds that trigger prion (show PRNP Antibodies)-like conversion.

  9. In summary, we have combined multiple data sets to identify transcripts, which are strong candidates for being phenotypic modifiers, and demonstrated SNCA is a modifier of pathology in motor neuron disease.

  10. In alpha-synuclein knock-out mice there was a decrease in neuronal glucose metabolism in cerebral cortex gray matter.

Human Synuclein, alpha (Non A4 Component of Amyloid Precursor) (SNCA) interaction partners

  1. Study suggests histones as prime candidates for one of the nuclear proaggregant factors involved in the formation of transmissible alpha-synuclein aggregates during neuron apoptosis.

  2. Study provides evidence that phosphorylated alpha-synuclein deposition is present in dermal nerve fibers in a subgroup of patients suffering from REM (show REM1 Antibodies) sleep behavior disorder, presumably representing prodromal Parkinson's disease.

  3. This review describes the major findings supporting the occurrence of alpha-synuclein pathology propagation in Parkinson's disease and discusses how this phenomenon could induce or contribute to synaptic injury and degeneration. [Review]

  4. This review evaluated major classes of molecular chaperones and their mechanisms relevant for preventing protein aggregation, specific case of alpha-synuclein aggregation. [review]

  5. Data suggest that endocytosis is the principal mechanism by which proteopathic alpha-synuclein aggregates are internalized in primary hippocampal neurons in culture; aggregates are rapidly trafficked along endosomal/lysosomal pathway, where most of the material remains for days as proposed in neurodegenerative synucleinopathies.

  6. Data suggest that endocytosis and lysosomal processing of proteopathic alpha-synuclein aggregates in neurons are consistent with models of neurodegeneration in synucleinopathies. [EDITORIAL]

  7. These results indicate that LRRK2 (show LRRK2 Antibodies) and alpha-synuclein participate in the dysregulation of CADPS2 (show CADPS2 Antibodies) by altering transcription and support the hypothesis that synaptic dysfunctions, through different mechanisms, might contribute to the neuronal defects of diseases such as Parkinson's disease.

  8. Increasing evidence supports that small alpha-synuclein aggregates or oligomers may be the real culprit, causing deficits in neurotransmission and neurogenesis in the hippocampus and related brain regions, which constitute the major mechanism for the hippocampal dysfunctions and associated neuropsychiatric manifestations in synucleinopathies. [alpha-synuclein]

  9. Most anti-PD1 (show PDCD1 Antibodies)-related adrenal insufficiency cases involved an isolated ACTH (show POMC Antibodies) deficiency. Eosinophilia may be an early indicator before the onset of symptoms.

  10. Significantly higher transcript expression levels of PD1 (show PDCD1 Antibodies) were found in tumor tissue, whilst a general increase in PDL1 (show CD274 Antibodies) expression was found in tumor tissues, although this did not reach statistical significance. Our study demonstrates higher levels of expression of PDL1 (show CD274 Antibodies) are associated with favorable clinical outcome.

Cow (Bovine) Synuclein, alpha (Non A4 Component of Amyloid Precursor) (SNCA) interaction partners

  1. analysis of membrane curvature sensing by amphipathic helices using alpha-synuclein and annexin B12 (show TNFAIP1 Antibodies) [ANXB12]

  2. Immunocytochemistry shows alpha synuclein localized to the Golgi apparatus and vesicles of bovine adrenal medullary chromaffin cells, consistent with its putative role in vesicular function within synapses.

Synuclein, alpha (Non A4 Component of Amyloid Precursor) (SNCA) Antigen Profile

Protein Summary

Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Four alternatively spliced transcripts encoding two different isoforms have been identified for this gene.

Gene names and symbols associated with SNCA

  • synuclein, alpha (non A4 component of amyloid precursor) (SNCA) antibody
  • alpha-synuclein (LOC100359228) antibody
  • alpha-synuclein-like (SNCA) antibody
  • synuclein, alpha (Snca) antibody
  • synuclein, alpha (non A4 component of amyloid precursor) (Snca) antibody
  • alphaSYN antibody
  • NACP antibody
  • PARK1 antibody
  • PARK4 antibody
  • PD1 antibody

Protein level used designations for SNCA

alpha SYN , alpha-synuclein , non-A beta component of AD amyloid , non-A4 component of amyloid , non A-beta component of AD amyloid , synuclein alpha-140 , alpha synuclein

GENE ID SPECIES
100053270 Equus caballus
100359228 Oryctolagus cuniculus
706985 Macaca mulatta
20617 Mus musculus
6622 Homo sapiens
29219 Rattus norvegicus
478478 Canis lupus familiaris
282857 Bos taurus
641350 Sus scrofa
395393 Gallus gallus
100725375 Cavia porcellus
100294604 Ovis aries
100190854 Pongo abelii
461375 Pan troglodytes
100984304 Pan paniscus
Did you look for something else?